(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 16.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Heron Therapeutics's revenue in 2026 is $155,097,000.On average, 6 Wall Street analysts forecast HRTX's revenue for 2026 to be $32,169,120,860, with the lowest HRTX revenue forecast at $30,548,196,165, and the highest HRTX revenue forecast at $33,500,332,769. On average, 5 Wall Street analysts forecast HRTX's revenue for 2027 to be $37,512,304,751, with the lowest HRTX revenue forecast at $33,801,047,305, and the highest HRTX revenue forecast at $43,262,553,441.
In 2028, HRTX is forecast to generate $45,154,854,668 in revenue, with the lowest revenue forecast at $38,023,886,187 and the highest revenue forecast at $56,354,637,511.